Portfolio company
Healome Therapeutics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops eye-drop matrix technology to improve drug delivery and treatment for patients with ocular surface diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Healome
Healome Therapeutics develops eye-drop matrix technology that restructures on the ocular surface to provide long-acting lubrication and drug delivery for patients with eye diseases.
INEYE Therapeutics
This company develops ocular drug delivery inserts to treat chronic eye conditions such as dry eye and glaucoma for patients.
GelMEDIX
GelMEDIX develops injectable hydrogel scaffolds and regenerative cell therapies to treat degenerative ocular diseases such as geographic atrophy for patients with vision loss.
Eyexora
This company develops therapeutics and medical devices for ophthalmic diseases to treat patients with vision-threatening conditions.
Kedalion Therapeutics
This company develops electromechanical ocular delivery devices for patients with eye conditions requiring precise topical medication administration.
Perfuse Therapeutics
The company develops sustained-release intravitreal therapies to treat ischemia-driven ocular diseases for patients with conditions like glaucoma and diabetic retinopathy.
Eyestem
The company develops cell replacement therapies to treat incurable blindness and retinal diseases for patients globally.
StemSight
This company develops stem cell therapies using biomaterials to treat corneal blindness in patients with limbal stem cell deficiency and other eye conditions.